Kieran O'Kane - Feb 8, 2023 Form 4 Insider Report for BIODESIX INC (BDSX)

Role
Chief Commercial Officer
Signature
/s/ Robin Harper Cowie as Attorney-in-Fact for Kieran O'Kane
Stock symbol
BDSX
Transactions as of
Feb 8, 2023
Transactions value $
-$3,596
Form type
4
Date filed
2/10/2023, 05:40 PM
Previous filing
Nov 21, 2022
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDSX Common Stock Options Exercise +5.46K +27.96% 25K Feb 8, 2023 Direct F1
transaction BDSX Common Stock Sale -$3.6K -2K -8% $1.80 23K Feb 9, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSX Restricted Stock Units Award $0 +122K $0.00 122K Feb 8, 2023 Common Stock 122K Direct F1, F4
transaction BDSX Restricted Stock Units Options Exercise $0 -1.49K -7.7% $0.00 17.9K Feb 8, 2023 Common Stock 1.49K Direct F1, F5
transaction BDSX Restricted Stock Units Options Exercise $0 -3.97K -33.33% $0.00 7.94K Feb 8, 2023 Common Stock 3.97K Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.
F2 These shares of Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs.
F3 The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
F5 These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
F6 These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.